Brain Cancer - Pediatric
Back to Oncology/Cancer Clinical Trials Main PageCPMC Cancer Services
| Principal Investigator/Contact Information | Protocol Title | Patient Population | Recruitment Period |
| Principal Investigator: CPMC Oncologists Contact: Catherine Carr 415-600-1369 | A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial. ACNS0331 Visit this study on ClinicalTrials.gov. | Pediatric patients with newly diagnosed standard risk Medulloblastoma | Open |
| Principal Investigator: CPMC Oncologists Contact: Catherine Carr 415-600-1369 | A Children Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens. ACNS02B3 Visit this study on ClinicalTrials.gov. | Pediatric patients with brain tumors | Open |
| Principal Investigator: CPMC Oncologists Contact: Catherine Carr 415-600-1369 | Concurrent Radiation and Temozolomide Followed By Temozolomide and Lomustine in the Treatment of High-Grade Gliomas. ACNS0423 Visit this study on ClinicalTrials.gov. | Pediatric patients with High- Grade Gliomas | Open |
| Principal Investigator: CPMC Oncologists Contact: Catherine Carr 415-600-1369 | Pilot Study Using Carboplatin, Vincristine and Temozolomide for Children Less Than or Equal to 10 Years of Age with Progressive/Symptomatic Low-Grade Gliomas. ACNS0223 Visit this study on ClinicalTrials.gov. | Pediatric patients less than or equal to 10 years of age with progressive/symptomatic Low Grade Gliomas. | Open |
| Principal Investigator: CPMC Oncologists Contact: Catherine Carr 415-600-1369 | Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients. ACNS0332 Visit this study on ClinicalTrials.gov. | Pediatric patients with other than average risk Meduloblastoma/PNET | Open |
| Principal Investigator: CPMC Oncologists Contact: Ron Frianeza 415-600-3027 | A Randomized Phase II Trial of Bevacizumab with Irinotecan or Bevacizumab with Temozolomide in Recurrent Glioblastoma. RTOG 0625 Visit this study on ClinicalTrials.gov. | Adult Subjects who have recurrent brain tumor. | Open |
updated 11/19/09
Back to top